May 28, 2018
Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Inclusion of the first patient in Phase 2b Study in Sarcopenia. Read the Press Release
Results of the 2018 Annual Meeting of Shareholders. Read the Press Release
Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
2017 Annual Financial Report made available. Read the Press Release
BIOPHYTIS updates on clinical development of Macuneos and presents its effects on visual function in a preclinical model of AMD at 2018 ARVO Congress. Read the Press Release
Biophytis files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami. Read the Press Release
Biophytis to participate in upcoming sectorial events over the first half of 2018. Read the Press Release